Background There is a move toward greater use of generic medicine in recent years, and loxoprofen sodium hydrate patches are often used in the field of orthopedic surgery. However, patientsʼ complaints of usage sensations and side effects differ between original medicine and generic medicine, and few reported basic investigations have yielded evidence for the causes of dermopathy with these medicines. Methods Loxoprofen sodium hydrate tapes and cataplasms, and ketoprofen tapes, were applied to 8︱week︱old female hairless mice. The patches were removed after 24 hours, and the skin was observed after 1 and 24 hours. Specifically, the number of abrasions triggered by skin irritation from the patches, horny layer water retention, exfoliation, epidermal thickness, and substance P expression were investigated. Results With loxoprofen sodium hydrate, greater skin damage was seen with tapes than with cataplasms. No differences were found between loxoprofen sodium hydrate preparations in any of the experiments. With Mohrus® tape the number of abrasions increased, horny layer moisture decreased, and the epidermis thickened compared with loxoprofen sodium hydrate. Conclusion Dermopathy with Mohrus® tape is thought to be affected by some substance derived from the tape. Even with loxoprofen sodium hydrate, patches have a stronger effect on the skin than non︱patch applications. This suggests that close attention to itching and inflammation is needed in patients with the dry skin characteristic of elderly people. Further study, for example on the pre︱application of moisturizing agents, is needed to identify appropriate patch sites for transdermal delivery systems.

塩酸イリノテカン（irinotecan hydrochloride: CPT-11）による重篤な好中球減少は，その代謝に関与するUGT1A1の遺伝子多型と関連することが報告されている。症例1 は70 歳，男性。直腸癌肝転移でmFOLFOX6 療法を6 コース施行したが，肝臓に再発を認めたためFOLFIRI 療法へ変更した。CPT-11 の投与量は150 mg/m2であった。1 コース目を施行したところ，day 12 にgrade 4 の好中球減少および39℃台の発熱を認めた。症例2 は65 歳，男性。S 状結腸癌肝転移に対してFOLFIRI 療法を開始した。CPT-11 の投与量は120 mg/m2であった。1 コース目のday 9 にgrade 3 の好中球減少および38℃台の発熱を認めた。症状改善後にUGT1A1 遺伝子多型を解析したところ，2 例はUGT1A1＊28 ホモ接合体を有していた。UGT1A1＊28 ホモ接合体を有する症例にFOLFIRI 療法を施行する時は，CPT-11 の投与量を120 mg/m2としても十分に注意が必要である。